Literature DB >> 14970827

Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor.

Jared W Young1, Keith Finlayson, Christopher Spratt, Hugh M Marston, Nicola Crawford, John S Kelly, John Sharkey.   

Abstract

In humans, nicotine has been shown to improve attention in both normal and impaired individuals. Observations in rats reflect some, but not all aspects of the nicotine-induced improvements in humans. To date these findings have not been replicated in mice. To examine the effect of nicotine on sustained attention in mice, we have established a version of the 5-choice serial reaction-time (5-CSR) task with graded levels of difficulty, based upon spatial displacement and a variable intertrial interval. Using this paradigm, microgram doses of nicotine produced a consistent reduction in the level of omissions and an improvement in proportion correct in normal mice. This improvement in sustained attention was made irrespectively of whether mice had previously received nicotine. In an attempt to elucidate which nicotinic acetylcholine receptor (nAChR) subtype(s) mediate this effect, we examined the performance of alpha7 nAChR knockout (KO) mice in the 5-CSR task. alpha7 nAChR KO mice not only acquired the task more slowly than their wild-type littermates, but on attaining asymptotic performance, they exhibited a higher level of omissions. In conclusion, by increasing the level of task difficulty, the performance of mice was maintained at sufficiently low levels to allow a demonstrable improvement in performance upon nicotine administration. Furthermore, as alpha7 KO mice are clearly impaired in the acquisition and asymptotic performance of this task, the alpha7 nAChR may be involved in mediating these effects of nicotine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14970827     DOI: 10.1038/sj.npp.1300393

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  84 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  Response requirement and increases in accuracy produced by stimulant drugs in a 5-choice serial reaction-time task in rats.

Authors:  Mikhail N Koffarnus; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

3.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.

Authors:  Amir H Rezvani; Marty Cauley; Hannah Sexton; Yingxian Xiao; Milton L Brown; Mikell A Paige; Brian E McDowell; Kenneth J Kellar; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 4.  CNTRICS final animal model task selection: control of attention.

Authors:  C Lustig; R Kozak; M Sarter; J W Young; T W Robbins
Journal:  Neurosci Biobehav Rev       Date:  2012-06-06       Impact factor: 8.989

5.  Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition.

Authors:  Timothy B Johnstone; Zhenglin Gu; Ryan F Yoshimura; Anne-Sophie Villegier; Derk J Hogenkamp; Edward R Whittemore; Jin-Cheng Huang; Minhtam B Tran; James D Belluzzi; Jerrel L Yakel; Kelvin W Gee
Journal:  J Pharmacol Exp Ther       Date:  2010-12-15       Impact factor: 4.030

Review 6.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

7.  Nicotine Addiction and Psychiatric Disorders.

Authors:  Munir Gunes Kutlu; Vinay Parikh; Thomas J Gould
Journal:  Int Rev Neurobiol       Date:  2015-09-19       Impact factor: 3.230

8.  Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E.

Authors:  Jessica A Siegel; Theodore S Benice; Peter Van Meer; Byung S Park; Jacob Raber
Journal:  Neurobiol Aging       Date:  2009-01-28       Impact factor: 4.673

Review 9.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 10.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.